Upexi (UPXI) Competitors $6.54 +0.86 (+15.09%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. SDGR, HROW, AMPH, NUVB, WVE, ETNB, TLRY, PGEN, RCUS, and NTLAShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics Schrodinger (NASDAQ:SDGR) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Does the media prefer SDGR or UPXI? In the previous week, Schrodinger had 1 more articles in the media than Upexi. MarketBeat recorded 8 mentions for Schrodinger and 7 mentions for Upexi. Schrodinger's average media sentiment score of 0.89 beat Upexi's score of 0.64 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upexi 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SDGR or UPXI? Schrodinger currently has a consensus target price of $27.83, indicating a potential upside of 48.72%. Upexi has a consensus target price of $15.50, indicating a potential upside of 137.11%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is SDGR or UPXI more profitable? Schrodinger has a net margin of -76.22% compared to Upexi's net margin of -135.86%. Schrodinger's return on equity of -45.70% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-76.22% -45.70% -24.81% Upexi -135.86%-535.19%-122.94% Do institutionals and insiders believe in SDGR or UPXI? 79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 21.0% of Schrodinger shares are owned by insiders. Comparatively, 4.4% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, SDGR or UPXI? Schrodinger has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500. Which has preferable earnings & valuation, SDGR or UPXI? Upexi has lower revenue, but higher earnings than Schrodinger. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M6.64-$187.12M-$2.48-7.55Upexi$26M14.81-$23.66MN/AN/A SummarySchrodinger beats Upexi on 10 of the 15 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$388.97M$2.93B$26.47B$10.13BDividend YieldN/A1.61%2.77%4.62%P/E RatioN/A24.2927.3526.13Price / Sales14.8161.54756.7491.41Price / CashN/A45.5327.0359.91Price / Book1.057.988.116.33Net Income-$23.66M$34.89M$199.14M$270.76M7 Day Performance8.23%15.89%10.75%3.50%1 Month Performance-1.85%14.49%22.91%6.83%1 Year Performance65.66%104.89%68.93%28.21% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi3.0254 of 5 stars$6.54+15.1%$15.50+137.1%+46.3%$388.97M$26M0.00130News CoverageShort Interest ↓Gap UpSDGRSchrodinger3.4223 of 5 stars$19.44+1.6%$27.83+43.2%-8.7%$1.41B$207.54M-7.84790HROWHarrow3.1157 of 5 stars$39.77+7.5%$64.67+62.6%-4.6%$1.37B$199.61M-159.08180Analyst RevisionAMPHAmphastar Pharmaceuticals3.9071 of 5 stars$29.26-0.5%$31.60+8.0%-36.4%$1.37B$731.97M10.962,028Positive NewsNUVBNuvation Bio2.6547 of 5 stars$3.48-10.9%$7.50+115.8%+9.1%$1.33B$7.87M-5.5260High Trading VolumeWVEWAVE Life Sciences4.5717 of 5 stars$7.58-8.6%$20.33+168.2%+21.4%$1.32B$108.30M-8.42240Positive NewsETNB89BIO2.6663 of 5 stars$8.57-3.4%$28.00+226.7%+6.7%$1.32BN/A-2.3740Positive NewsTLRYTilray Brands2.7018 of 5 stars$1.12-5.9%$1.94+73.0%-38.4%$1.31B$821.31M-0.482,842Short Interest ↓Gap UpPGENPrecigen4.5885 of 5 stars$4.16-4.6%$8.25+98.3%+325.5%$1.30B$4.34M-9.90190Positive NewsRCUSArcus Biosciences1.7623 of 5 stars$11.43-6.3%$21.14+85.0%-32.2%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.3436 of 5 stars$11.84-1.8%$29.05+145.4%-43.6%$1.29B$57.88M-2.52600Analyst Revision Related Companies and Tools Related Companies SDGR Alternatives HROW Alternatives AMPH Alternatives NUVB Alternatives WVE Alternatives ETNB Alternatives TLRY Alternatives PGEN Alternatives RCUS Alternatives NTLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
